Jamouss Kevin T, Damanakis Alexander Ioannis, Cornwell Abigail C, Jongepier Martine, Trujillo Maria A, Pflüger Michael Johannes, Kawalerski Ryan, Maalouf Alexandre, Hirose Katsuya, Datta Shalini, Sipes Abigail, Pedro Brian A, Gudmundsson Emma, Assarzadegan Naziheh, Engle Logan, Scharpf Robert B, Kawamoto Satomi, Thompson Elizabeth D, Wood Laura D
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Graduate School of Life Sciences, Utrecht University, Utrecht, The Netherlands.
J Pathol. 2025 May;266(1):40-50. doi: 10.1002/path.6402. Epub 2025 Feb 25.
Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to late-stage diagnoses. To improve patient outcomes, early intervention in precursor lesions such as intraductal papillary mucinous neoplasm (IPMN) is crucial. However, early intervention must be balanced against overtreatment of low-risk lesions that are unlikely to progress, underscoring the need to better understand molecular alterations in neoplastic cells and changes in the tumor microenvironment (TME) that drive the progression of IPMNs. In this study, we characterized alterations in the TME of IPMNs as they progressed to high-grade dysplasia, using immunohistochemistry to quantify immune cell density and activation status in more than 100 well-characterized human IPMN samples. Analyses revealed progression to a more immunosuppressive TME in high-grade IPMN compared with low-grade IPMN, characterized by elevated expression of immune checkpoint molecules (PD-L1, TIM3, VISTA), increased density of macrophages, and decreased density of cytotoxic T cells. Intriguingly, the alterations in macrophages were limited to focal regions of high-grade dysplasia, while T-cell alterations affected the entire IPMN. Additionally, elevated VISTA expression was associated with poorer clinical outcome after IPMN resection in an independent cohort. These findings provide important insights into the interplay between the immune microenvironment and IPMN progression, highlighting potential targets to modify the TME for cancer interception. © 2025 The Pathological Society of Great Britain and Ireland.
由于胰腺癌的诊断往往处于晚期,胰腺导管腺癌(PDAC)构成了重大挑战。为了改善患者的治疗效果,对导管内乳头状黏液性肿瘤(IPMN)等前驱病变进行早期干预至关重要。然而,早期干预必须在不过度治疗低风险、不太可能进展的病变之间取得平衡,这凸显了更好地了解肿瘤细胞中的分子改变以及驱动IPMN进展的肿瘤微环境(TME)变化的必要性。在本研究中,我们利用免疫组织化学对100多个特征明确的人类IPMN样本中的免疫细胞密度和激活状态进行量化,以此来描述IPMN进展为高级别发育异常时TME的变化。分析显示,与低级别IPMN相比,高级别IPMN的TME向更具免疫抑制性发展,其特征为免疫检查点分子(PD-L1、TIM3、VISTA)表达升高、巨噬细胞密度增加以及细胞毒性T细胞密度降低。有趣的是,巨噬细胞的变化仅限于高级别发育异常的局部区域,而T细胞的变化则影响整个IPMN。此外,在一个独立队列中,VISTA表达升高与IPMN切除术后较差的临床结果相关。这些发现为免疫微环境与IPMN进展之间的相互作用提供了重要见解,突出了改变TME以进行癌症拦截的潜在靶点。© 2025英国和爱尔兰病理学会